Back to top
more

Blueprint Medicines (BPMC)

(Delayed Data from NSDQ)

$113.69 USD

113.69
661,965

-1.29 (-1.12%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BPMC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 711 945 477 872 484
Receivables 43 37 37 25 23
Notes Receivable 0 0 0 0 0
Inventories 21 30 22 9 0
Other Current Assets 33 35 18 22 10
Total Current Assets 808 1,047 554 928 517
Net Property & Equipment 42 33 31 34 38
Investments & Advances 84 161 558 678 64
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 41 27 20 11 15
Total Assets 1,049 1,350 1,252 1,718 708
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 5 3 8 4 5
Current Portion Long-Term Debt 30 17 0 0 0
Current Portion Capital Leases 0 0 0 0 7
Accrued Expenses 128 131 122 106 89
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 40 22 12 13 6
Total Current Liabilities 215 183 150 131 106
Mortgages 0 0 0 0 0
Deferred Taxes/Income 5 14 25 29 40
Convertible Debt 0 0 0 0 0
Long-Term Debt 209 122 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 409 423 3 7 8
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 919 835 281 248 243
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,474 2,358 2,250 2,107 1,412
Retained Earnings -2,340 -1,833 -1,275 -631 -945
Other Equity -4 -10 -4 -5 -3
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 131 515 971 1,470 464
Total Liabilities & Shareholder's Equity 1,049 1,350 1,252 1,718 708
Total Common Equity 131 515 971 1,470 464
Shares Outstanding 60.79 59.83 58.80 55.70 49.20
Book Value Per Share 2.15 8.60 16.51 26.39 9.44

Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 648 711 713 723
Receivables NA 60 43 41 38
Notes Receivable NA 0 0 0 0
Inventories NA 31 21 16 17
Other Current Assets NA 38 33 37 33
Total Current Assets NA 777 808 808 811
Net Property & Equipment NA 42 42 41 37
Investments & Advances NA 115 84 142 142
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 33 41 39 39
Total Assets NA 1,038 1,049 1,105 1,106
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 5 5 7 7
Current Portion Long-Term Debt NA 30 30 30 18
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 107 128 110 101
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 52 40 38 32
Total Current Liabilities NA 207 215 197 169
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 5 5 5 5
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 209 209 208 122
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 409 408 412
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 728 919 903 795
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,565 2,474 2,434 2,411
Retained Earnings NA -2,251 -2,340 -2,229 -2,095
Other Equity NA -4 -4 -3 -4
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 311 131 203 311
Total Liabilities & Shareholder's Equity NA 1,038 1,049 1,105 1,106
Total Common Equity 0 311 131 203 311
Shares Outstanding 62.62 61.20 60.70 60.70 60.60
Book Value Per Share 0.00 5.08 2.15 3.34 5.13